ArticleFrontiers in medicine2021
The Global, Regional, and National Burden of Psoriasis: Results and Insights From the Global Burden of Disease 2019 Study.
Article in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07234838 (Influence of Anti-Psoriatic Biologic Therapies Targeting TNF-α and Interleukins 17 and 23 on the Risk of Development and Recurrence of Anogenital Warts), which is not on this map. Cited by 189 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Influence of Anti-Psoriatic Biologic Therapies Targeting TNF-α and Interleukins 17 and 23 on the Risk of Development and Recurrence of Anogenital Warts: A Retrospective and Prospective Study With an Exploratory Component on HPV Vaccination Acceptability (CONDYPSO)
Who cites it
189 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Health-related quality of life in patients with psoriasis in Asian countries: a systematic review and meta-analysis of EQ-5D utility scores.Scientific reports · 2026Pooled it
- Comparative efficacy and safety of IL-23 p19 monoclonal antibodies for plaque psoriasis: a bayesian network meta-analysis of randomized controlled trials.Frontiers in immunology · 2026Pooled it
- Psychological impact and quality of life in pediatric patients with chronic skin disorders: a systematic review (2010-2025).Frontiers in pediatrics · 2026Pooled it
- Evaluation of the risk of heart failure with tumour necrosis factor inhibitors: A large-scale meta-analysis in immune-mediated inflammatory diseases.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Pooled it
- The prevalence and risk of allergic rhinitis in psoriasis patients: a systematic review and meta-analysis.Scientific reports · 2025Pooled it
- Subclinical Myocardial Dysfunction Assessment Using Speckle Tracking Echocardiography in Patients With Psoriasis: A Pilot Meta-Analysis.Clinical cardiology · 2024Pooled it
- Harnessing Big Data, Smart and Digital Technologies and Artificial Intelligence for Preventing, Early Intercepting, Managing, and Treating Psoriatic Arthritis: Insights From a Systematic Review of the Literature.Frontiers in immunology · 2022Pooled it
- Efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled trial.Chinese medical journal · 2026Trial
- Bimekizumab efficacy and safety in Chinese patients with psoriasis in the BE SHINING Phase 3 study.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Trial
- Efficacy and safety of ME3183, an oral phosphodiesterase 4 inhibitor, in patients with plaque psoriasis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Trial
- Advanced hydrogel-based drug delivery systems for psoriasis management: From material design to multi-target therapies.International journal of pharmaceutics: X · 2026Review
- Enhanced Anti-inflammatory Effects of 18β-Glycyrrhetinic Acid and Hesperetin for the Treatment of Psoriasis: Evidence from LPS-stimulated RAW264.7 Cells and Imiquimod-induced Psoriasis Mouse Model.Applied biochemistry and biotechnology · 2026Article
- Understanding Social Drivers of Health Among US Adults with Psoriasis from Different Races and Ethnicities.Dermatology and therapy · 2026Article
- Sodium R-lipoate protects against psoriatic skin inflammation via modulating IL-23/IL-17A axis, oxidative stress, and mast cell activation.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Clinical Outcomes in a Longitudinal Virtual Dermatology Care Model for Eczema and Psoriasis.Dermatology practical & conceptual · 2026Article
- Shikonin-Loaded ROS-Responsive Microneedles for Psoriasis Therapy: Formulation, Transdermal Delivery, and Mechanistic Evaluation.Pharmaceutics · 2026Article
- Spatially Profiling Trace Cytokine Signatures From Microscopically Derived Skin Samples to Probe Skin Disease Inflammation.Small methods · 2026Article
- Impact of vitamin D receptor gene variants on psoriasis vulgaris susceptibility and clinical phenotype in a Greek population.Experimental and therapeutic medicine · 2026Article
- Cost-Effectiveness Analysis of Bimekizumab against Interleukin-23 Inhibitors in Patients with Plaque Psoriasis in Japan.Dermatology and therapy · 2026Article
- Psoriasis-Obesity-Related Gene COX7C Promotes Keratinocyte Proliferation and Positively Regulates Inflammatory Responses in Psoriasis.Journal of cellular and molecular medicine · 2026Article
129 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.